246 related articles for article (PubMed ID: 22381921)
1. Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox.
Parker S; Chen NG; Foster S; Hartzler H; Hembrador E; Hruby D; Jordan R; Lanier R; Painter G; Painter W; Sagartz JE; Schriewer J; Mark Buller R
Antiviral Res; 2012 Apr; 94(1):44-53. PubMed ID: 22381921
[TBL] [Abstract][Full Text] [Related]
2. Buccal viral DNA as a trigger for brincidofovir therapy in the mousepox model of smallpox.
Crump R; Korom M; Buller RM; Parker S
Antiviral Res; 2017 Mar; 139():112-116. PubMed ID: 28039021
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model.
Parker S; Touchette E; Oberle C; Almond M; Robertson A; Trost LC; Lampert B; Painter G; Buller RM
Antiviral Res; 2008 Jan; 77(1):39-49. PubMed ID: 17904231
[TBL] [Abstract][Full Text] [Related]
4. Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.
Parker S; Schriewer J; Oberle C; Robertson A; Lanier R; Painter G; Buller RM
Antivir Ther; 2008; 13(7):863-73. PubMed ID: 19043920
[TBL] [Abstract][Full Text] [Related]
5. Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus.
Parker S; Crump R; Foster S; Hartzler H; Hembrador E; Lanier ER; Painter G; Schriewer J; Trost LC; Buller RM
Antiviral Res; 2014 Nov; 111():42-52. PubMed ID: 25128688
[TBL] [Abstract][Full Text] [Related]
6. Mousepox in the C57BL/6 strain provides an improved model for evaluating anti-poxvirus therapies.
Parker S; Siddiqui AM; Oberle C; Hembrador E; Lanier R; Painter G; Robertson A; Buller RM
Virology; 2009 Mar; 385(1):11-21. PubMed ID: 19100593
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model.
Hutson CL; Kondas AV; Mauldin MR; Doty JB; Grossi IM; Morgan CN; Ostergaard SD; Hughes CM; Nakazawa Y; Kling C; Martin BE; Ellison JA; Carroll DS; Gallardo-Romero NF; Olson VA
mSphere; 2021 Feb; 6(1):. PubMed ID: 33536322
[TBL] [Abstract][Full Text] [Related]
8. A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challenge.
Parker S; D'Angelo J; Buller RM; Smee DF; Lantto J; Nielsen H; Jensen A; Prichard M; George SL
Antiviral Res; 2021 Nov; 195():105179. PubMed ID: 34530009
[TBL] [Abstract][Full Text] [Related]
9. A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease.
Israely T; Paran N; Lustig S; Erez N; Politi B; Shafferman A; Melamed S
Virol J; 2012 Jun; 9():119. PubMed ID: 22709563
[TBL] [Abstract][Full Text] [Related]
10. A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus.
Stabenow J; Buller RM; Schriewer J; West C; Sagartz JE; Parker S
J Virol; 2010 Apr; 84(8):3909-20. PubMed ID: 20130052
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of cidofovir treatment of mice infected with ectromelia (mousepox) virus encoding interleukin-4.
Robbins SJ; Jackson RJ; Fenner F; Beaton S; Medveczky J; Ramshaw IA; Ramsay AJ
Antiviral Res; 2005 Apr; 66(1):1-7. PubMed ID: 15781125
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans.
Rice AD; Adams MM; Wallace G; Burrage AM; Lindsey SF; Smith AJ; Swetnam D; Manning BR; Gray SA; Lampert B; Foster S; Lanier R; Robertson A; Painter G; Moyer RW
Viruses; 2011 Jan; 3(1):47-62. PubMed ID: 21373379
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model.
Buller RM; Owens G; Schriewer J; Melman L; Beadle JR; Hostetler KY
Virology; 2004 Jan; 318(2):474-81. PubMed ID: 14972516
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans.
Rice AD; Adams MM; Lampert B; Foster S; Robertson A; Painter G; Moyer RW
Viruses; 2011 Feb; 3(2):63-82. PubMed ID: 21369346
[TBL] [Abstract][Full Text] [Related]
15. [THE USE OF THE MODEL MOUSE ICR--VARIOLA VIRUS FOR EVALUATION OF ANTIVIRAL DRUG EFFICACY].
Titova KA; Sergeev AA; Kabanov AS; Bulychev LE; Sergeev AA; Galakhova DO; Shishkina LN; Zamedyanskaya AS; Nesterov AE; Glotov AG; Taranov OS; Omigov VV; Agafonov AP; Sergeev AN
Vopr Virusol; 2016; 61(2):79-84. PubMed ID: 27451500
[TBL] [Abstract][Full Text] [Related]
16. Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses.
Quenelle DC; Prichard MN; Keith KA; Hruby DE; Jordan R; Painter GR; Robertson A; Kern ER
Antimicrob Agents Chemother; 2007 Nov; 51(11):4118-24. PubMed ID: 17724153
[TBL] [Abstract][Full Text] [Related]
17. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.
Yang G; Pevear DC; Davies MH; Collett MS; Bailey T; Rippen S; Barone L; Burns C; Rhodes G; Tohan S; Huggins JW; Baker RO; Buller RL; Touchette E; Waller K; Schriewer J; Neyts J; DeClercq E; Jones K; Hruby D; Jordan R
J Virol; 2005 Oct; 79(20):13139-49. PubMed ID: 16189015
[TBL] [Abstract][Full Text] [Related]
18. Ectromelia virus: the causative agent of mousepox.
Esteban DJ; Buller RML
J Gen Virol; 2005 Oct; 86(Pt 10):2645-2659. PubMed ID: 16186218
[TBL] [Abstract][Full Text] [Related]
19. Oral 1-O-octadecyl-2-O-benzyl-sn-glycero-3-cidofovir targets the lung and is effective against a lethal respiratory challenge with ectromelia virus in mice.
Hostetler KY; Beadle JR; Trahan J; Aldern KA; Owens G; Schriewer J; Melman L; Buller RM
Antiviral Res; 2007 Mar; 73(3):212-8. PubMed ID: 17123638
[TBL] [Abstract][Full Text] [Related]
20. Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge.
Russo AT; Berhanu A; Bigger CB; Prigge J; Silvera PM; Grosenbach DW; Hruby D
Vaccine; 2020 Jan; 38(3):644-654. PubMed ID: 31677948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
